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RESEARCH ARTICLE
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To address challenges in the diagnosis of cognitive dysfunction (CD) related to systemic lupus
erythematosus–associated (SLE-associated) autoimmune mechanisms rather than confounding
factors, we employed an integrated approach, using resting-state functional (FDG-PET) and
structural (diffusion tensor imaging [DTI]) neuroimaging techniques and cognitive testing, in adult
SLE patients with quiescent disease and no history of neuropsychiatric illness. We identified resting
hypermetabolism in the sensorimotor cortex, occipital lobe, and temporal lobe of SLE subjects,
in addition to validation of previously published resting hypermetabolism in the hippocampus,
orbitofrontal cortex, and putamen/GP/thalamus. Regional hypermetabolism demonstrated
abnormal interregional metabolic correlations, associated with impaired cognitive performance,
and was stable over 15 months. DTI analyses demonstrated 4 clusters of decreased microstructural
integrity in white matter tracts adjacent to hypermetabolic regions and significantly diminished
connecting tracts in SLE subjects. Decreased microstructural integrityin the parahippocampal gyrus
correlated with impaired spatial memory and increased serum titers of DNRAb, a neurotoxic autoantibody
associated with neuropsychiatric lupus. These findings of regional hypermetabolism, associated
with decreased microstructural integrity and poor cognitive performance and not associated
with disease duration, disease activity, medications, or comorbid disease, suggest that this is
a reproducible, stable marker for SLE-associated CD that may be may be used for early disease
detection and to discriminate between groups, evaluate response to treatment strategies, or assess
disease progression.
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Cognitive dysfunction (CD) is one of the most common of the 19 neuropsychiatric lupus (NPSLE) syndromes and manifests insidiously over time, as opposed to the more dramatic presentations of acute confusional state, stroke, and psychosis (1, 2). CD in systemic lupus erythematosus (SLE) affects multiple cognitive domains, including attention, executive function, verbal and nonverbal learning, working memory,
and psychomotor function; it is associated with significantly increased morbidity and decreased quality of
life (3–6). The diagnosis of CD and correct attribution to SLE-associated mechanisms rather than other
potentially confounding factors, such as infection, metabolic disturbances, medication effects, mood disturbances, and toxins, have been compromised by the poor sensitivity and specificity of available diagnostic
tools. Additionally, the wide variability of CD prevalence in lupus, ranging from 3% to 80%, is ascribed to
differences in testing metrics, subject demographics and comorbidities, and small sample sizes (7). These
conflicting reports highlight the need for unbiased and objective assessments of, or biomarkers for, CD
attributable to SLE that can be used for diagnosis and assessment of response to treatment.
Proposed mechanisms for CD include chronic neurotoxic effects of brain-reactive autoantibodies
directed against N-methyl D aspartate receptors (cross-reactive anti-dsDNA/NMDAR antibodies, termed
DNRAb) (8, 9), ribosomal P, and neuronal surface P antigen and direct effects of cytokines (10–13). In a
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murine model, DNRAb bind activated NMDARs, allowing excessive calcium influx and resulting in neuronal dysfunction or death, depending on antibody concentration (14). NMDARs are located throughout
the cortex but have highest density in the hippocampus; it has also been shown that DNRAb specifically
target place cells in the CA-1 area of the hippocampus, with resulting deleterious effects on spatial memory
in mice and human disease (14, 15).
Fluorine-18 fluorodeoxyglucose PET ([18F]FDG-PET) is a functional imaging technique that measures cellular glucose uptake. Alterations in CNS glucose metabolism may reflect cell density, infection,
inflammation, and/or abnormal cell function. We have reported previously that SLE subjects with stable
disease activity and without known CNS disease demonstrate a pattern of increased resting metabolism in
the hippocampus, orbitofrontal cortex, and basal ganglia (16) that correlated with serum DNRAb titers,
memory impairment, and mood alterations. A complementary neuroimaging technique, diffusion tensor
imaging (DTI), is an advanced MRI technique based on the diffusion of water molecules in tissue that
allows for assessment of white matter (WM) integrity and structure. Several cross-sectional studies of DTI
in NPSLE and SLE patients without neuropsychiatric symptoms, compared with healthy controls, suggest
an overall decrease in WM integrity in both SLE groups (reviewed in ref. 17). However, combining imaging
results for all NPSLE syndromes precludes the ability to evaluate individual CNS manifestations in the
context of proposed biologic mechanisms.
We therefore sought to continue our neuroimaging characterization of CD in SLE and visualize structural and metabolic changes that might embody a biomarker for SLE-associated pathophysiological processes. Based on our previously reported set of regional metabolism changes in SLE that correlated with
neuropsychiatric performance (16), we (a) validated those original findings in a new cohort and a larger
combined cohort; (b) defined changes in underlying tract microstructure in the new cohort; (c) assessed longitudinal changes in brain metabolism and microstructure in these individuals; and (d) related the observed
changes to cognitive performance and other variables, such as disease duration and serum DNRAb levels.
We continue to focus on SLE patients with no known history of an acute clinical NPSLE manifestation
or other CNS event in order to avoid confounding influences from other NPSLE-related or unrelated syndromes that may be driven by different underlying mechanisms.

Results
Clinical characteristics of SLE groups 1 and 2
Thirty-seven adult SLE subjects were recruited. Data from the first 17 SLE subjects (group 1 [SLE-1]) were
published previously (16). Both groups were similar for all measured parameters, except for anti-Ro antibodies, which were less frequent in SLE-1 (Table 1), and disease duration. The SLE-1 group had been stratified by disease duration of less than or equal to 2 years (n = 9) or greater than or equal to 10 years (n = 8).
The mean disease duration in those with disease for longer than or equal to 10 years was 16.25 ± 6.78 years
(range 10–28 years). Because regional brain hypermetabolism did not correlate with disease duration in
our previous study (16), SLE-2 subjects were not stratified by disease duration. The mean disease duration
for the SLE-2 group was 13.8 ± 9.19 years with a range of 2–33 years. In terms of potential confounding
influences on cognition, disease activity and corticosteroid doses were very low, hypertension was well controlled and distributed equally between groups, coronary artery disease was rare, no subjects had diabetes,
and smoking occurred equally between groups. The mean prednisone dose was 2.5 ± 3.4 mg, with a range
of 0–10 mg. Based on body surface area, physiologic daily doses of prednisone for the SLE subjects would
range from 2.1 to 4.8 mg daily, and 84% of them were on a daily dose of less than or equal to 5 mg daily.
One subject in each group had anticardiolipin antibodies, and none had a lupus anticoagulant. Clinical
data for the 13 SLE subjects included in the longitudinal assessments at baseline (time 1 [T1]) and time 2
(T2) are presented in Table 2. There were no significant changes in disease activity (SLEDAI scores), damage (SLICC DI scores), or medication use at the times the assessments were performed. Between T1 and
T2, 5 of the 13 SLE subjects experienced a SLE flare requiring medication changes; 2 switched to different
disease-modifying drugs; and 3 added disease-modifying drugs.

Cognitive and behavioral testing of SLE groups 1 and 2
There were no differences in mean throughput scores for the Automated Neuropsychological Assessment
Metric (ANAM) subtests between the SLE groups (Table 1). However, although the SLE subjects had no
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Table 1. Subject characteristics for SLE-1 and SLE-2
Age (yr)
Sex: female
Ethnicity/race
Latino/Hispanic
Asian
African American
White
Education (yr)
SLEDAI score
SLICC DI score
Current medications
Prednisone dose (mg)
Hydroxychloroquine
DMARDA
Serology
Anti-dsDNA ab+
Anti-Ro+
Anti-NMDAR+
Anti-ribosomal P+
ACL (IgG, M, or A)
Comorbid disease
Hypertension
Coronary artery disease
Smoking: ever
BMI
Mood assessments
STAIB
BDI
ANAM testing
Match-to-Sample
Matching Grids
CPTC

SLE-1 (n = 17)

SLE-2 (n = 20)

P value

37.5 ± 9.4
17 (100%)

41 ± 10.3
18 (90%)

0.286
0.489

7 (41%)
1 (6%)
7 (41%)
2 (12%)
13.5 ± 4.3
2.7 ± 2.6
0.8 ± 0.8

4 (20%)
1 (5%)
14 (70%)
1 (5%)
13.3 ± 2.4
2.3 ± 2.1
0.9 ± 1.1

0.160
0.906
0.078
0.564
0.839
0.560
0.675

2.4 ± 3.1
12 (71%)
10 (59%)

2.6 ± 3.7
17 (85%)
11 (55%)

0.821
0.428
1.000

10 (59%)
7 (30%)
11 (65%)
2 (13%)
1(6%)

10 (50%)
16 (70%)
9 (45%)
3 (15%)
1 (5%)

0.743
0.021
0.325
1.000
0.459

4 (24%)
1 (6%)
4 (24%)
26.5 ± 5.0

9 (45%)
1 (5%)
7 (35%)
28.7 ± 5.3

0.300
1.000
0.495
0.195

35.8 ± 9.9
8.9 ± 8.5

31.2 ± 9.1
7.4 ± 5.4

0.151
0.495

21.4 ± 11.2
27.9 ± 10
74.2 ± 36.3

20.8 ± 7.2
27.1 ± 8.0
70.3 ± 17.1

0.834
0.783
0.685

Disease-modifying anti-rheumatic drug; for SLE-1, methotrexate (n = 2), azathioprine (n = 3), mycophenolate mofetil
(n = 5); for SLE-2, methotrexate (n = 1), azathioprine (n = 3), mycophenolate mofetil (n = 7). BState Trait Anxiety
Inventory, evaluates current anxiety. CRunning memory continuous processing test. SLE-1, SLE group 1; SLE-2, SLE
group 2; BDI, Beck Depression Inventory; ANAM, Automated Neuropsychological Assessment Metric.

A

prior diagnosis of cognitive impairment, in comparison with healthy control normative data (ANAM GNS
Battery: Administration Manual and ANAM4 GNS: User Manual, Vista LifeSciences, unpublished observations), the SLE subjects demonstrated significantly lower scores on all 3 ANAM subtests (P = 0.000 for
the Match-to-Sample and Matching Grids test and P = 0.006 for the Running Memory Continuous Performance Test [CPT]). The Match-to-Sample subtest assesses visuospatial perception and working memory.
89% of the SLE subjects (82% of SLE-1, 95% of SLE-2, P = 0.315) scored lower than the normative mean
for this subtest and 19% (23% of SLE-1, 15% of SLE-2, P = 0.68) scored less than 2 SDs below the normative mean. The Matching Grids test assesses spatial processing efficiency. 92% of the SLE subjects (88% of
SLE-1, 95% of SLE-2, P = 0.584) scored lower than the normative mean for this subtest, and 41% (41% of
SLE-1, 40% of SLE-2, P = 1.0) scored less than 2 SDs below the normative mean. The CPT assesses vigilance and sustained attention. 70% of the SLE subjects (53% of SLE-1, 85% of SLE-2, P = 0.069) scored
lower than then normative mean for this subtest, and 13% (23% of SLE-1, 5% of SLE-2, P = 0.159) scored
less than 2 SDs below the mean. Both SLE groups had similar mean scores for depression and anxiety
(Table 1); however, these did not reach cut off points associated with clinically significant symptoms (18,
19). The Beck Depression Inventory (BDI) has a range of scores from 0 to 63 (18). In SLE-1, the range for
BDI scores was 0 to 31; 13 subjects (76%) had BDI scores indicative of no depression (BDI scores 0–13);
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Table 2. Clinical characteristics and cognitive test results of the 13 subjects in SLE-2 with imaging at T1
and T2, a mean of 14.9 months apart (range 11.3–19.1 months)
SLEDAI score
SLICC DI score
Current medications
Prednisone dose (mg)
Hydroxychloroquine
DMARDA
Mood assessments
STAIB
BDI
ANAM testing
Match-to-Sample
Matching Grids
CPTC

T1 (n = 13)

T2 (n = 13)

P value

1.9 ± 1.7
1.1 ± 1.1

3.0 ± 2.8
1.4 ± 1.6

0.116
0.104

2.9 ± 4.1
10 (77%)
8 (62%)

3.2 ± 3.8
10 (77%)
11 (85%)

0.828
1.000
0.250

30.5 ± 9.6
6.0 ± 4.5

33.8 ± 12.7
7.5 ± 5.8

0.437
0.291

19.9 ± 7.1
27.0 ± 8.9
71.2 ± 20.2

23.4 ± 8.3
32.4 ± 11.2
74.6 ± 20.1

0.016
0.036
0.496

Disease-modifying anti-rheumatic drug; for SLE-1, methotrexate (n = 2), azathioprine (n = 3), mycophenolate mofetil
(n = 5); for SLE-2, methotrexate (n = 1), azathioprine (n = 3), mycophenolate mofetil (n = 7). BState Trait Anxiety
Inventory, evaluates current anxiety. CRunning memory continuous processing test. T1, time 1; T2, time 2; BDI, Beck
Depression Inventory; ANAM, Automated Neuropsychological Assessment Metric.

A

2 (12%) had scores indicative of mild depression (BDI scores 14 – 19); 1 (6%) had a score indicative of
moderate depression (BDI scores 20–28); and 1 (6%) had a score indicative of severe depression (BDI ≥29).
Similarly, in the SLE-2 group, the range of BDI scores was 0 to 16; 15 (75%) had scores indicative of no
depression; and 5 (25%) had scores indicative of mild depression. The range of scores for the State Trait
Anxiety Inventory (STAI) measure is 20–80 and a score ≥ 40 indicates increased anxiety (19). In the SLE1 group, the range of scores was 20 to 52; 11 (65%) of subjects had scores indicative of no anxiety; and 6
(35%) had higher scores. For SLE-2, the range of scores was 20 to 50; 15 (75%) had scores of less than 40;
and 5 (25%) had scores indicative of increased anxiety. The differences between groups for anxiety (P =
0.719) and depression (P = 0.361) were not significant.
No significant differences were observed between T1 and T2 for the behavioral testing in the longitudinal studies (Table 2). Performance on two of the ANAM subtests, Match-to-Sample and Matching Grids,
improved between T1 and T2 but still remained significantly below the normative mean scores.

Hypermetabolic regions identified in the combined SLE-1 and SLE-2 groups
Use of identical study methods allowed us to combine the FDG-PET data from SLE-1 and SLE-2 groups in a
whole-brain, voxel-wise approach to compare the combined 37 SLE (SLE-1/2) and 25 healthy control (HC-1/2)
subjects. SLE subjects demonstrated resting hypermetabolism (Figure 1 and Table 3) in the hippocampus (Figure 1, A and B; P < 0.001), orbitofrontal cortex (BA 11) (Figure 1, C and D; P < 0.002), and putamen/globus
pallidus/thalamus (putamen/GP/thalamus) (Figure 1E; P < 0.001), the same regions originally identified in the
SLE-1 group (16) and independently validated in the SLE-2 group (Supplemental Data and Supplemental Table
1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.124002DS1). No
significant differences were found between SLE-1 and SLE-2 subjects in these regions (P > 0.41). Identification
of resting hypermetabolism in these same regions in SLE from the combined groups validates our previous
results and, importantly, demonstrates the reproducibility and stability of the methodology.
Analysis of the combined groups, SLE-1/2 and HC-1/2, also identified 3 new hypermetabolic regions
(Table 3): the sensorimotor cortex (SMC) (Figure 1F; P < 0.001), occipital lobe (BA 19) (Figure 1G; P
< 0.002), and temporal lobe (BA 37) (Figure 1H; P < 0.001). No significant metabolic differences were
present between SLE-1 and SLE-2 subjects in these hypermetabolic regions (P > 0.10). Moreover, hypermetabolism in the hippocampus and orbitofrontal cortex was highly abnormal bilaterally (P < 0.001). Hypermetabolism in the other 4 regions, though unilaterally abnormal at P < 0.001, was also abnormal in the
contralateral hemisphere at a lower significance level (P < 0.005).Longitudinal analysis of a subgroup of 13
SLE-2 subjects with baseline and follow-up FDG-PET scans demonstrated unchanged resting hypermetabolism (P > 0.21) in all 6 regions over a mean of 14.9 months.
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Figure 1. Abnormal hypermetabolic regions in SLE. Top: Voxel-wise comparison of the FDG-PET scans between the combined SLE-1/2 cohorts (n = 37)
and healthy controls (HCs; n = 25) revealed significant increases in resting glucose metabolism in SLE subjects in the hippocampus (A and B), orbitofrontal
cortex (BA 11) (C and D), and putamen/GP/thalamus (E), the same regions independently identified in SLE-1 (1) and SLE-2 (Supplemental Data). Three new
hypermetabolic regions identified in the SLE-1/2 subjects include the SMC (F), occipital lobe (BA 19) (G), and temporal lobe (BA 37) (H). (Peak voxel of each
cluster was significant at P < 0.001, uncorrected. Clusters for the hippocampus, putamen/GP/thalamus, and SMC were also significant at P < 0.05, corrected for cluster extent [Table 3]. Clusters were displayed using a red-yellow scale thresholded at P < 0.005 superimposed on a MRI template.). Bottom:
Metabolism in these regions was significantly higher (P < 0.002) in the SLE-1/2 subjects (triangles) than in the healthy controls (circles) but not different
between the SLE-1 (white triangles) and SLE-2 (black triangles) subjects (P > 0.41). (Error bar represents standard error of the mean. Arrow represents
Student’s t test of SLE-1/2 subjects vs. HCs.)

Altered interregional metabolic relationships in SLE and functional associations
Interregional metabolic correlations were examined among the 6 hypermetabolic regions identified from
the SLE-1/2 and HC-1/2 analyses. HC-1/2 subjects demonstrated significant interregional metabolic correlations between the hippocampus and putamen/GP/thalamus (r = 0.60, P < 0.002), the hippocampus
and temporal lobe (r = 0.40, P < 0.05), and the putamen/GP/thalamus and temporal lobe (r = 0.49, P
< 0.02) (Figure 2A). SLE-1/2 subjects also demonstrate a significant metabolic correlation between the
hippocampus and putamen/GP/Thalamus (r = 0.45, P < 0.006). However, other interregional metabolic
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Table 3. Brain regions with significant differences in metabolic activity between 37 SLE subjects from the combined groups 1 and 2
(SLE-1/2) and 25 healthy controls (HC-1/2)
CoordinatesA

Brain region
Hippocampus
Orbitofrontal cortex (BA 11)
Putamen/GP/thalamus
Sensorimotor cortex (BA 3/4)
Occipital lobe (BA 19)
Temporal lobe (BA 37)

Right
Left
Right
Left
Right
Right
Left
Right

x
28
–28
30
–16
30
4
–32
30

y
–20
–24
40
44
–12
–38
–72
–58

z
–2
0
–14
–18
4
74
8
–14

ZmaxB
4.69C
4.56C
3.50
3.88
4.68C
3.96C
3.45
3.56

HC (n = 25)
1.31 (0.07)D
1.35 (0.07)
1.55 (0.07)
1.45 (0.05)
1.57 (0.08)
1.47 (0.12)
1.20 (0.07)
1.67 (0.07)

SLE (n = 37)
1.40 (0.06)F
1.43 (0.06)F
1.62 (0.09)E
1.52 (0.07)F
1.66 (0.07)F
1.60 (0.12)F
1.28 (0.11)E
1.74 (0.07)F

Montreal Neurological Institute standard space (60). BSignificant at P < 0.001 (peak voxel, uncorrected), SPM5 2-sample t test. CSignificant at P < 0.05,
corrected for cluster extent, SPM5 2-sample t test. DMean (SD) regional metabolism. EP < 0.01, FP < 0.001, Student’s t test of SLE subjects vs. HC group. BA,
Brodmann area; GP, globus pallidus; HC, healthy controls; SLE, systemic lupus erythematosus.
A

correlations in the SLE-1/2 subjects shift away from the temporal lobe, as seen in the HCs, to include significant correlations between the SMC and hippocampus (r = 0.38, P < 0.03) and putamen/GP/thalamus (r
= 0.34, P < 0.04) (Figure 2B). There were no significant interregional correlations between the orbitofrontal
cortex (HC: P > 0.07; SLE: P > 0.19) and the occipital lobe (HC: P > 0.13; SLE: P > 0.14) and any other
hypermetabolic regions identified in SLE-1/2. These results suggest that a normal resting pattern of interregional metabolic relationships is altered among abnormal hypermetabolic regions in SLE.
Correlations between metabolic activity in the 6 hypermetabolic regions and clinical and behavioral
measures in the SLE-1/2 subjects were also examined. Poor performance on the running memory CPT, a
measure of working memory and attention, correlated with increased resting metabolism in the hippocampus (r = –0.35, P < 0.04), validating the previously reported relationship between these two measures (16).
We also found new inverse correlations of poor performance on the CPT with increased metabolism in
other hypermetabolic areas, including the SMC (r = –0.42, P < 0.02), putamen/GP/thalamus (r = –0.32, P
= 0.05), temporal lobe (r = –0.35, P < 0.04), and occipital lobe (r = –0.39, P < 0.02). Depression (r = 0.36,
P < 0.03) and anger (r = 0.34, P < 0.04) on the ANAM mood scale correlated with hypermetabolism in the
orbitofrontal cortex. Additionally, the SLICC Damage Index correlated with abnormal hypermetabolism
in the hippocampus (r = 0.37, P < 0.03). Mean scores on the CPT test did not change significantly between
T1 (71.2 ± 20.2) and T2 (74.6 ± 20.1) (P = 0.496) in the 13 SLE-2 subjects with repeat scans (Table 2).

Correlations of regional metabolism with disease duration
In our prior study of SLE-1 subjects (16), decreased metabolism in the prefrontal (BA 9 and 10) and premotor
(BA6) cortex correlated significantly with longer disease duration. In the SLE-1/2 subjects, similar inverse
correlations with disease duration and metabolism were found in the prefrontal cortex (BA 9: r = –0.35, P <
0.04; BA 10: r = –0.30, P = 0.07) and premotor cortex (BA 6, r = – 0.66, P < 0.0001). Among the 6 hypermetabolic regions in SLE-1/2, disease duration correlated only modestly with hypermetabolism in the SMC (r =
0.33, P < 0.05). These results suggest that decreasing metabolism in the prefrontal and premotor cortices may
be a function of disease chronicity and damage rather than active immune–related processes.

DTI results
Microstructural changes — cross-sectional and longitudinal. Significant reductions in fractional anisotropy (FA)
in the SLE-2 group, relative to 14 age- and sex-matched HCs (HC-3) (P < 0.001), identified 5 discrete
regions, or clusters, with abnormal WM microstructure in the SLE-2 subjects (Figure 3 and Table 4). The
clusters in the parietal lobe, the cingulum (hippocampus), and the splenium corpus callosum (CC) were
significant at P < 0.001, corrected for cluster extent at P < 0.05. Cluster 1 was localized to the WM tracts
in the parietal lobe, which is a part of the superior longitudinal fasciculus (SLF) connecting the frontal,
occipital, parietal, and temporal lobes. Cluster 2 was localized to the WM tracts in the vicinity of the insular cortex, which is a part of the uncinate fasciculus (UF), connecting parts of the limbic system, such as
insight.jci.org   https://doi.org/10.1172/jci.insight.124002

6

RESEARCH ARTICLE

Figure 2. Altered pattern of interregional metabolic correlations between abnormal hypermetabolic regions in SLE. (A) Healthy controls (HC) demonstrate a normal pattern of interregional metabolic correlations such that resting metabolism among the hippocampus, putamen/GP/thalamus, and
temporal lobe are all significantly correlated (filled arrows; P < 0.05). (B) In contrast, while the significant hippocampal-putamen/GP/thalamic metabolic
relationship (P < 0.006) is preserved in SLE, other significant metabolic correlations shift away from the temporal lobe to include the SMC (P < 0.04).

the hippocampus and amygdala in the temporal lobe, with frontal lobe elements, such as the orbitofrontal
cortex. Cluster 3 was localized to the WM tracts in the occipital lobe, which is a part of the cingulum that is
connected to the hippocampus and a part of the inferior longitudinal fasciculus (ILF), which is connected
to the temporal lobe and occipital lobe. Cluster 4 was in the WM tracts in the frontal lobe, which is a part
of the inferior frontal occipital fasciculus (IFOF). The last abnormal region, cluster 5, was localized in the
WM tracts in the parietal lobe, which is a part of the splenium of CC. Of note, the FA reductions observed
in these regions were also significant (P < 0.05) in homologous areas in the contralateral brain.
To evaluate the spatial relationships of clusters with significantly abnormal WM microstructure (low
FA) in the SLE-2 group with corresponding hypermetabolic gray matter regions in these patients, we overlaid statistical parametric maps of the SLE-2 and HC-3 group contrasts, thresholded at T = 3.0 (P < 0.005)
for metabolic activity (SLE > HC) and FA (SLE < HC) on a common MRI template (Figure 4). We found
that 4 of the clusters with significant SLE-related FA reductions (the SLF parietal cluster, the UF insular
cluster, the ILF occipital cluster, the IFOF frontal cluster, see Figure 3 and Table 4) lay in close proximity to
areas of SLE-related hypermetabolism in the adjacent gray matter (Figure 4, yellow ellipses).
There were no significant changes in microstructural integrity FA values over a mean of 14.9 months in
the subgroup of 13 SLE subjects with follow-up scans (P > 0.3, paired t tests) in all 5 WM regions (Table 4).
Localization of tract changes. Each of the abnormal FA clusters was used as a seed region for fiber tracking. In each pathway, fewer tracts were visualized in the SLE-2 compared with HC-3 subjects (Figure 5).
SLE-2 subjects demonstrated reduced tract numbers in the SLF (temporal part) (−74%), the UF (−86%),
the cingulum (hippocampus part) (−82%), the ILF (–99.5%), IFOF (–100%), and the splenium CC (−48%).
Correlations between microstructural integrity and serum DNRAb titers and spatial memory performance. As expected, performance of SLE-2 subjects on the 2x2 spatial memory task (2x2SMT) (74%% ± 13% correct) was significantly worse than on the 2x2 nonspatial memory task (93% ± 11% correct; P = 0.014). We examined relationships among serum DNRAb titers, 2x2SMT performance, and microstructural integrity. Serum DNRAb
titer was entered as a covariate in a voxel-wise search for regions in which FA correlated with serum DNRAb
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Figure 3. Regions with abnormal microstructure in SLE subjects. Significant reductions (P < 0.001) in FA were present in the following brain areas (top):
1, white matter tracts in the parietal lobe, a part of the superior longitudinal fasciculus (SLF); 2, white matter tracts in the vicinity of the insular, a part of
the uncinate fasciculus (UF); 3, white matter tracts in the occipital lobe/cingulum (hippocampus); 4, white matter tracts in the frontal lobe, a part of the
inferior frontal occipital fasciculus (IFOF); and 5, white matter tracts in the parietal lobe, a part of the splenium of corpus callosum (CC). Individual cluster
fractional anisotropy (FA) values for the SLE and control groups were plotted (bottom). All group differences were highly significant (P < 0.001). The details
of these brain regions were presented in Table 4.

titer. A significant correlation (P < 0.002) was identified in the bilateral parahippocampal area (BA 36/BA 20,
Figure 6A, yellow/red). Mean FA in these areas exhibited a negative correlation (r = –0.64, P < 0.002) with
serum DNRAb titers (Figure 6B) and a positive correlation (r = 0.63, P < 0.002) with 2x2SMTscores (Figure
6B). Moreover, a significant inverse correlation (r = –0.46, P < 0.05) was found between hypermetabolism
in the hippocampus, identified in the FDG-PET studies of the same SLE-2 subjects (Supplemental Table 1),
and 2x2 SMT scores. In aggregate, these data suggest that poor performance on the spatial memory task is
significantly associated with hippocampal hypermetabolism and decreased microstructural integrity in the
parahippocampal region that is also associated with high serum DNRAb titers.

Discussion
We have employed an integrated approach, using resting-state functional and structural neuroimaging techniques and neuropsychological testing, to characterize CD in lupus patients with quiescent, stable disease
and no known history of acute NPSLE or CNS dysfunction. Despite the absence of a known diagnosis of
NPSLE syndromes, the majority of SLE subjects enrolled in this study scored below the mean of healthy
control normative data on the ANAM subtests, consistent with prior reports of the high prevalence of
CD in SLE (20). This is an important distinction, given the associations reported here among cognitive
performance, abnormal brain resting metabolism, and structure. We have validated our initial findings of
abnormal resting hypermetabolism in the hippocampus, orbitofrontal cortex, and putamen/GP/thalamus
of SLE subjects as well as in 3 new regions: the SMC, occipital lobe, and temporal lobe. The resting pattern
of interregional metabolic relationships among these hypermetabolic areas is abnormally skewed in SLE
compared with HC subjects, and hypermetabolism in 5 of the regions correlates significantly with impaired
performance on a test of working memory. Consistent with the metabolic data, FA analysis reveals 4 clusters of decreased microstructural integrity localized in WM tracts adjacent to the hypermetabolic regions,
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Table 4. Brain regions with significant differences in FA between 14 healthy controls (HC-3) and 19 SLE-2
subjects at baseline (TP1) and stability of FA measures in 13 SLE-2 subjects over a mean of 15 months
from TP1 to TP2
Brain region
Parietal lobe, left, SLF
Insular, left, UF
Cingulum (hippocampus),
left, ILF
Frontal lobe, left, IFOF
Parietal lobe, right,
Splenium CC

x

CoordinatesA
y

z

ZmaxB

HC (n = 14)

–33
-36
–18

–35
5
–69

22
–13
–1

4.66C
4.33
4.29C

–31
17

33
–57

8
38

4.02
3.96C

0.38 (0.03)D
0.28 (0.03)
0.32 (0.03)

SLE TP1 (n
= 19)
0.32(0.03)
0.23(0.02)
0.25(0.02)

SLE TP2 (n
= 13)
0.32 (0.03)
0.22 (0.03)
0.24 (0.02)

0.38 (0.02)
0.40 (0.02)

0.34(0.02)
0.32(0.06)

0.34 (0.02)
0.32 (0.06)

Montreal Neurological Institute standard space (60). BSignificant at P < 0.001 (peak voxel, uncorrected), cluster extent
test. CSignificant at P < 0.05, corrected for for cluster extent test. DMean (SD) regional fractional anisotropy (FA). In all
5 brain regions, when comparing SLE-2 with healthy control subjects, P < 0.001, Student’s t test. FA was also assessed
in the same clusters in 13 of the SLE-2 subjects a mean of 15 months later at TP2. When comparing FA in all 5 clusters
from these 13 SLE-2 subjects at TP1 to TP2, P > 0.3, paired Student’s t test. HC, healthy controls; SLE, systemic lupus
erythematosus; TP, time point; SLF, superior longitudinal fasciculus; UF, uncinate fasciculus; ILF, inferior longitudinal
fasciculus; IFOF, inferior frontal occipital fasciculus; CC, corpus callosum.
A

and the connecting tracts are significantly diminished in the SLE subjects. Decreased microstructural integrity in the parahippocampal gyrus correlates with impaired spatial memory and increased serum DNRAb
titers. In aggregate, these results suggest that CD in SLE is characterized by a diffuse process that results in
reproducible resting hypermetabolism in several gray matter regions and disruption of normal resting metabolic patterns that associate with (a) poor performance on cognitive testing and (b) clusters of decreased
microstructural integrity that are connected by diminished WM tracts. While many inflammatory molecules associated with SLE have the potential to damage neurons through direct neurotoxicity, microglial
activation, or other mechanisms (10, 12, 13), it is not surprising that antibodies targeting the NMDA receptor (DNRAb) are significantly associated with impaired spatial memory and abnormalities in glutamatergic
brain regions, such as the hippocampus and parahippocampus.
There have been many studies utilizing FDG-PET imaging in SLE and a variety of NPSLE syndromes
that, in contrast to our results, have reported regional hypometabolism in the frontal, temporal, parietal, and
parietal-occipital regions (21–25). Regional gray matter hypermetabolism has been reported rarely in the striatal
nuclei and basal ganglia, typically in the clinical context of SLE patients with choreoathetoid movements (23,
26, 27). Several important differences in methodology may account for the dissimilarities with our results. Each
of these previous studies has imaged SLE subjects with active disease, with or without NPSLE (focal deficits,
acute confusional state, mood disorders, CD, seizures), with attendant treatment regimens, including high doses
of glucocorticoids and immunosuppressive medications. The analyses done in these studies have been based on
measures of glucose metabolism in prespecified regions of interest (ROIs), which were applied to each scan,
and comparisons were either between active SLE and active NPSLE or healthy controls. Our analytic approach
employed an unbiased, voxel-wise search of whole-brain volumes to directly compare SLE and healthy control
subjects. This approach may have allowed for greater sensitivity and objectivity in detecting differences between
groups than an approach that uses predetermined ROIs. Additionally, we studied SLE subjects with no history
of active or prior CNS events, relatively few significant comorbid diseases, or high levels of antiphospholipid antibody titers, with low/stable disease activity, thereby avoiding confounding influences of medications,
comorbid disease, and disease activity, whether neuropsychiatric or peripheral. The reproducibility of regional
hypermetabolism in the hippocampus, orbitofrontal cortex, and putamen/GP/thalamus in both the separate
and combined SLE cohorts validates the stability of our methodology and suggests that hypermetabolism represents a SLE-associated biologic process in these regions. Interestingly, several prior FDG-PET studies reported follow-up scans that demonstrated improvement or normalization of the previously found hypometabolic
regions in subjects with clinical improvement (23–25). It is therefore likely that the regional hypometabolism was
a function of acute illness, whether a specific NPSLE syndrome or not, as it is known that many inflammatory
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Figure 4. Spatial proximity of white matter regions with abnormal reductions in fractional anisotropy in SLE-2
patients and areas of increased metabolic activity in adjacent gray matter. White matter regions with abnormal
reductions in fractional anisotropy are represented in green (clusters 1–4, see Figure 3 and Table 4); areas of increased
metabolic activity in adjacent gray matter are represented in red (see Figure 1 and Table 3. Adjacent gray and white
matter regions are encompassed by yellow ellipses. (Clusters represent areas with significant differences in local
fractional anisotropy [FA] or metabolic activity in SLE vs. healthy control subjects [thresholded at T = 3.0, P < 0.005],
overlaid on the MNI152 T1 MRI template.).

molecules associated with disease flares can affect CNS function (reviewed in ref. 12). Follow-up scans in 13 of
our SLE subjects, with low disease activity at the time of imaging, demonstrated no significant change over a
mean of 14.9 months, despite evidence of increased interim SLE disease activity in 5 of these 13 subjects. These
data suggest that the persistent hypermetabolism may be intrinsic to SLE and is not associated with disease duration or disease activity. This is in contrast to the hypometabolic regions in the prefrontal and premotor cortices,
identified in all 3 SLE groups, that correlated with disease duration, suggesting an association between hypometabolism and chronic damage. We hypothesize that the stability of the regional metabolic overactivity appears to
be a reproducible, stable marker for SLE-related CD that may be responsive to targeted therapies and therefore
potentially useful as an outcome measure in a clinical trial.
Increased PET signal indicates metabolic overactivity that may represent regional neuronal activity,
local inflammatory or oncogenic activity, or disinhibition after damage to remote but connected regions
(28–31). Turning to preclinical experiments for guidance, it has been demonstrated in micro–FDG-PET
studies of nonautoimmune mice immunized to produce serum DNRAb that affected mice have decreased
metabolism in the hippocampus in the first 2 weeks after blood-brain barrier disruption, coincident with
histological study of neuronal toxicity and death. This is followed over 9 weeks by steadily increasing
hippocampal metabolism that correlates inversely with hippocampal CA1 neuron number, verified with
unbiased quantitative histopathology. These findings suggest a delayed tissue response —
 either a cominsight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Figure 5. White matter pathways associated with the abnormal SLE-related regions visualized with group tractography. The superior longitudinal
fasciculus (temporal part) (SLF) (noted as 1), uncinate fasciculus (UF) (noted as 2), cingulum (hippocampus part) and inferior longitudinal fasciculus (ILF)
(noted as 3), inferior frontal occipital fasciculus (IFOF) (noted as 4), and the splenium of the corpus callosum (CC) (noted as 5) pathways reconstructed in
the healthy control (left) and SLE (right) groups. Fewer tracts were visualized in the SLE group relative to the controls in the SLF (temporal part) (−74%),
UF (−86%), cingulum (hippocampus part) (−82%), ILF (–99.5%), IFOF (–100%), and splenium CC (−48%).

pensatory neuronal mechanism or an inflammatory mechanism such as recruitment of microglial cells
to sites of neuronal necrosis (32). These preclinical data provide a cautionary tale in the interpretation of
cross-sectional human data. We have identified several abnormal hypermetabolic regions in SLE that do
not associate with age, disease duration, current medication use, or disease activity; that exhibit abnormal
metabolic relationships between each other; and associate with poor performance on a memory task, but
we cannot know whether the hypermetabolism is representative of a compensatory neuronal response,
decreased inhibitory input from another damaged region, or a microglial response to damaged neurons or
other inflammatory molecules.
This is relevant to the shift in interregional metabolic relationships away from the temporal lobe to
include the SMC that we report in SLE subjects. Possible explanations for this shift include damage to the
temporal lobe, damage to the SMC with influx of microglial cells, and compensatory neuronal response
or damage elsewhere resulting in decreased inhibitory input to the SMC. Nonetheless, these data suggest,
perhaps, an erosion of normal, resting-state brain activity that characterizes SLE patients and associates
with impaired performance on cognitive testing. Once a significant resting pattern has been identified, particularly one that is not associated with disease duration, disease activity, medications, or comorbid disease,
it may be used for early disease detection, to discriminate between groups, to evaluate response to treatment
strategies, or to assess disease progression.
Integration of the PET metabolic data and the DTI structural data suggests correlations between
regional hypermetabolism and areas of diminished WM microstructural integrity that may account for
the shift in interregional metabolic relationships. DTI analyses identified 4 WM clusters: the parietal lobe
involving the SLF, the insula involving the UF, the occipital lobe involving the ILF, and the frontal lobe
involving the IFOF. These areas of abnormally decreased FA in WM were in close proximity to hypermetabolic regions in the adjacent gray matter (Figure 4, ellipses). For each of these projection pathways,
tractography (see Methods) revealed fewer tracts in the SLE-2 sample relative to HC-3 control subjects.
Our interpretation of these compelling data is that the original insult may take place in the hypermetabolic,
gray matter regions, followed by disruption of the WM tracts connecting them. Additional longitudinal
studies are needed to verify this prediction. While several studies have reported WM alterations in NPSLE
compared with HC subjects in segments of the CC, the forceps, anterior corona radiata, thalamus, and
parietal and frontal lobes (33–36) and overall diminished volume of the CC (34, 37), our results support the
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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Figure 6. Microstructural integrity (FA) in the parahippocampus regions correlates with serum DNRAb titers and performance on a spatial memory test
in SLE subjects. (A) Regression analysis of voxel-wise correlations between FA maps and serum DNRAb titers revealed a significant inverse correlation
between FA values in the bilateral parahippocampal gyrus (BA 36/BA 20; yellow/red areas) and serum DNRAb titers. (B) Mean microstructural integrity in
the bilateral parahippocampal gyrus exhibited a negative correlation with serum DNRAb titers (r = –0.64, P < 0.002, left). Mean microstructural integrity in
the bilateral parahippocampal gyrus also exhibited a positive correlation with performance on a spatial memory test (r = 063, P < 0.002, right). Pearson’s
product-moment correlation coefficient was used to evaluate the correlations between FA values and serum DNRAb titers and 2x2SMT scores.

growing body of literature demonstrating significant WM abnormalities in SLE subjects without acute neuropsychiatric manifestations (38–42). Most of these studies in SLE subjects without neuropsychiatric manifestations failed to demonstrate significant correlations between diminished WM integrity and cognition.
However, Shapira-Lichter et al. have reported impaired performance on a learning and verbal memory task
that correlated with decreased integrity of WM tracts in the CC and cingulum in SLE subjects without
neuropsychiatric symptoms (40). We have identified a significant correlation between reduced FA in the
parahippocampal gyrus, poor performance on a spatial memory task, and elevated serum DNRAb titers.
Poor performance on the 2x2SPMT also correlated with hippocampal hypermetabolism. These results suggest the importance of selective cognitive testing based on biologic mechanisms rather than predetermined
cognitive batteries that may not capture the specific cognitive deficit related to a particular mechanism. The
hippocampus, the center for memory processing and storage (43), is one of the regions with reproducible
hypermetabolic results that we have identified in SLE subjects. Hippocampal abnormalities have been well
described in SLE patients and animal models. In human SLE, hippocampal atrophy, presumably reflective
of neuronal loss, has been correlated with cognitive deficits (38, 44–48) as well as specific autoantibodies,
including DNRAb (44, 49). Our findings of reproducible hippocampal hypermetabolism with functional
correlates extend these previous reports, suggesting an SLE-mediated attack on the hippocampus. In animal models, neuronal damage and atrophy in the hippocampus in lupus mice correlates with impaired spatial learning (50) that is prevented with immunosuppressive therapy (51). Selective targeting of hippocaminsight.jci.org   https://doi.org/10.1172/jci.insight.124002
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pal neurons by DNRAb in the mouse model, specifically place cells in the CA1 region of the hippocampus,
results in cognitive and spatial memory deficits (15, 52). We previously reported a significant association in
SLE patients between serum DNRAb titers and impaired performance on the 2x2SMT (15). We currently
report a significant correlation between performance on the 2x2SMT and hippocampus metabolism. In
addition, identification of correlations between reduced microstructural integrity in the parahippocampal
gyrus and poor performance on the 2x2SMT as well as high serum DNRAb titers in SLE subjects further
supports the hypothesis that antibody-mediated neuronal toxicity may induce damage to the hippocampal
region that results in disorganization and reduced integrity of the WM outflow tract through the parahippocampus and manifests functionally as impaired spatial memory.
Our study is limited by the use of historical healthy controls; although they are age- and sex-matched
and their PET/MRI imaging protocols were identical to those used for the SLE subjects, we do not have
cognitive testing on these individuals or information regarding ethnicity, race, and socioeconomic status.
Additionally, the lack of functional imaging during cognitive testing limits our interpretations to asynchronous correlations between task performance and integrity of the neuroanatomy. This was an intentional
choice, as we are unable to ensure subject motivation during testing in a scanner; however, we acknowledge
that functional imaging during testing would provide additional valuable information.
In summary, this is the first study to our knowledge to examine both gray and WM abnormalities together
in SLE in concert with cognitive assessments. We have used structural and functional imaging to demonstrate
the reproducibility of regional resting hypermetabolism in several areas of the brain that is unchanged over a
mean of 14.9 months, which may represent a resting metabolic signature for intrinsic SLE-associated pathology that correlates with CD. The associated DTI studies identified WM clusters with reduced microstructural
integrity that were connected by significantly diminished tracts, several of which were adjacent to the hypermetabolic regions. Moreover, relationships among serum DNRAb, hippocampal glucose metabolism, microstructural integrity in the parahippocampus, and performance on spatial memory tasks suggest that an initial
insult occurring in gray matter may lead to decreased integrity of WM outflow tracts, resulting in impaired
memory function. In this case it may be DNRAb that is the inciting factor but many other inflammatory
molecules, including IFN-α, IFN-γ, IL-1β, IL-6, and others have been implicated (10, 12, 13). Continued longitudinal studies are necessary to prove our hypothesis as are other types of imaging studies to determine the
contributions of neuronal versus microglial cell activity to regional hypermetabolism. To avoid confounding
influences on our cognitive, behavioral, and imaging outcomes, we have restricted our subject population;
however, it will also be useful to validate our findings in SLE patients with a broader spectrum of disease
activity to see if changes in disease activity or medications alter the resting metabolic signature.

Methods
Study design
This is a prospective, observational study designed to evaluate associations among brain regional resting metabolism, microstructural integrity, serum DNRAb titers, and performance on cognitive testing in SLE subjects
with quiescent disease and no history of CNS insult or known neuropsychological illness. Assessments were
performed at baseline and after a mean of 15 months in the SLE subjects. Imaging studies from SLE subjects
were compared with imaging studies from age- and sex-matched historical healthy control subjects.

Subject selection
SLE subjects in groups 1 and 2. Thirty-seven SLE subjects were recruited from the Rheumatology Clinics at
the Feinstein Institute for Medical Research (FIMR). All were 18 years of age or older and fulfilled American College of Rheumatology revised criteria for SLE (53). FDG-PET imaging data from the first 17 SLE
subjects (group 1; SLE-1) were published previously (16). Data from the newly recruited 20 SLE subjects
(group 2; SLE-2), studied under the same FDG-PET imaging protocol as SLE-1, were used separately
and in combination with those from group 1 for the validation studies. In addition to baseline FDG-PET
imaging, SLE-2 subjects also had MRI-DTI at baseline and repeat PET and DTI studies a mean of 14.9
(range 11.3–19.1 months) months later. To avoid confounding influences on neuroimaging and neuropsychological endpoints, key exclusion criteria included the presence of active or prior NPSLE or other CNS
event; structural abnormalities on MRI; current use of antidepressant, antipsychotic, or anxiolytic drugs;
or history of illicit drug use. Additionally, SLE subjects were required to have stable disease activity and
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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medication doses for 4 weeks prior to assessments. Group 1 recruitment was also stratified by disease duration, with presence of disease for less than 2 or more than 10 years. As disease duration did not contribute
to regional brain hypermetabolism (1), group 2 subjects were not stratified by disease duration.
Healthy control subjects. For FDG-PET studies, we studied 25 healthy control (HC-1/2) subjects, including the 17 HC subjects (HC-1) in the previously published study of the SLE-1 subjects (16) and 8 HC subjects (HC-2; 2 newly recruited and 6 selected historical HCs at the Center for Neurosciences in the FIMR),
matched for sex and age to the SLE-2 subjects. For MRI-DTI studies, 14 age- and sex-matched healthy controls (HC-3) were selected from a historical cohort of diffusion MRI studies at the FIMR. As the majority of
HC subjects (23 of 25) were selected from an imaging historical healthy control cohort established at the Center for Neurosciences in the FIMR, we were able to match for sex and age but not for ethnicity, race, BMI, and
socioeconomic status even though race, BMI, and socioeconomic status have been reported to influence structural brain development (54, 55). The HC subjects also did not perform the cognitive and behavioral testing.

Assessments
Clinical, cognitive, and behavioral assessments for SLE subjects. Disease activity and accrued damage were assessed
with the Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index
(SELENA-SLEDAI) (56) and the Systemic Lupus International Collaborating Clinics Damage Index (SLICC
DI) (57) within 2 weeks of imaging and cognitive assessments. CD was assessed with the ANAM (58), a
computerized battery of measures of sustained attention, visual search, computational skills, concentration,
cognitive processing, and working memory. The following ANAM subtests were selected for this study the
Matching Grids test, a measure of spatial processing efficiency, where two designs are shown sequentially and
the viewer is asked to determine if they are the same as or different from each other; the Match-to-Sample
test, a measure of visuospatial perception and working memory, where the subject is asked to select which
of two checkerboard matrix designs match a target checkerboard matrix design presented 5 seconds earlier;
and the CPT, a measure of vigilance and sustained attention where a running set of numbers is presented in a
randomized sequence. For this test, the subject is asked to continuously monitor the numbers and determine
if each new number is the same as or different from the preceding number (59).
Throughput scores for each ANAM subtest, representing a combination of reaction time and accuracy,
were the primary measure of cognitive efficiency used in the analyses. As data for the majority of HC subjects was obtained from a historical healthy control cohort, they did not undergo cognitive and behavioral
testing. Normative data from community and college subjects was used for comparison with the SLE subject data. We did not assign a strict cutoff for cognitive impairment but report the percentages of SLE subjects scoring less than the normative mean or 2 SDs below the normative mean. The raw throughput scores
for the ANAM tests were used in the analyses. SLE subjects were rated for depression and anxiety with the
BDI (18, 60), STAI (19), and the ANAM mood domain assessments. The 2x2SMT assessed both object
recognition and memory for spatial relations (Supplemental Figure 1) (15). All assessments were completed at baseline and repeated in 13 of the SLE-2 subjects after a mean of 14.9 months. Four of the SLE-2 subjects withdrew from the longitudinal study, and all of the remaining 16 SLE-2 subjects underwent follow-up
assessments; however, both the research MRI and PET scanners at the institution were replaced during that
time. To alleviate concerns associated with analyses of data derived from different scanners, only follow-up
data for 13 SLE subjects with repeat studies on the original scanners are presented here.
PET. At baseline, all 37 SLE (20 SLE-2 and 17 SLE-1) and 25 HC-1/2 subjects (men/women: 2/23,
age 40.7 ± 12.9 years) underwent FDG-PET imaging following an overnight fast, as described elsewhere
(61). Thirteen of the twenty SLE-2 subjects had repeat FDG-PET scans on the same scanner 11–19 months
from baseline (mean 14.9 months). Scanning was conducted in 3D mode using the GE Advance tomograph (General Electric Medical Systems) at the FIMR. Autoradiographic PET images were acquired for
20 minutes beginning 35 minutes after the injection of 3.5 mCi FDG in an eyes-open rest state in a dimly
lit room with minimal auditory stimulation. FDG-PET images were preprocessed using Statistical Parametric Mapping (SPM5, https://www.fil.ion.ucl.ac.uk/spm/software/spm5; Institute of Neurology, London, United Kingdom) running in MATLAB (MathWorks), as described previously (16, 62). Baseline and
repeat scans from the 13 SLE-2 subjects were realigned. Individual images of all SLE and HC subjects
were normalized and nonlinearly warped into the Talairach space using a standard PET template and then
smoothed with an isotropic Gaussian kernel (10 mm) in all directions to improve the signal- to-noise ratio.
Investigators were blinded to subject identity and clinical status during data acquisition and analysis.
insight.jci.org   https://doi.org/10.1172/jci.insight.124002
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MRI-DTI. Nineteen of the twenty SLE-2 subjects (men/women: 2/17, age 45.12 ± 10.58 years) and
14 HC-3 subjects (men/women: 2/12, age 42.02 ± 10.72 years) underwent MRI in the Signa HDxt 3.0
T scanner (GE Healthcare) at North Shore University Hospital, with an 8-channel head coil. Thirteen
(men/women: 0/13, age 43.91 ± 9.73 years) of the nineteen SLE-2 subjects had repeat scans a mean of
14.9 months later. For DTI, a single-shot spin-echo echo planar imaging sequence was used with 33 diffusion gradient directions and 5 B0 images. The b value in the diffusion-weighted images was 800 s/mm2.
The FOV was 240 mm, 55 slices were acquired with 2.5-mm thickness, TE = 82.7 ms, TR = 15 seconds,
flip angle = 90°, and scan time = 9.5 min. The 128 × 128 images were 0 filled to a matrix size 256 × 256,
yielding an image resolution of 0.9 × 0.9 × 2.5 mm3. For high-resolution T1-weighted structural scans, the
FOV was 240 mm, 176 slices were acquired with 1-mm thickness, the imaging matrix was 256 × 256, flip
angle = 8°, TR = 7.6 ms, TE = 2.9 ms, inversion time = 650 ms, with resolution of 0.9 × 0.9 × 1 mm3. After
DTI acquisition, the following DTI processing steps were performed using the FMRIB library (http://
www.fmrib.ox.ac.uk/fsl/). Diffusion-weighted images were corrected for eddy current distortions and head
motion using the eddy current correction routine in (EDDY) (63). Nonbrain tissue was removed from the
images using the brain extraction tool (BET2). Diffusion tensor for each brain voxel and FA map were
determined for all subjects using DTIFIT. B0 image was registered to the Montreal Neurological Institute
(MNI-152: 1 × 1 × 1 mm3) template using a 12-parameter affine transformation (FLIRT) (64). The resulting
transformation was then applied to the FA map to register it to MNI space. Once aligned, the FA images
were smoothed using a kernel of 8 mm (FWHM) for group comparison and regression analysis.
FA was chosen specifically as the optimal measure for WM structural integrity, as it reflects WM fiber
density, axonal diameter, and myelination. Four commonly used measures of DTI include FA, mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) (65). These measures directly relate to the
value of the 3 eigen values (λ1, λ2, λ3) of the tensor, with different individual properties. MD is a measure
preferentially used to probe gray matter microstructure because gray matter tissue lacks directional diffusion, whereas FA, RD, and AD are used to assess WM microstructure due to inherent directional diffusivity present in WM (66). Although AD is more specific for axonal degeneration and RD is more specific for
demyelination, FA is highly sensitive to microstructural WM changes (65) and was therefore selected to
assess the WM changes in SLE patients in this paper.

Statistics
Baseline characteristics of SLE subjects and ANAM throughput scores were analyzed using Student’s t
tests or nonparametric Mann-Whitney U tests, χ2 tests, or Fisher’s exact test, as appropriate. Relationships
among resting regional metabolism, ANAM scores, and clinical parameters were examined using Pearson’s
correlations. Differences between T1 and T2 for the longitudinal studies were analyzed with paired t tests
or the Exact McNemar test. Analyses were performed using SAS9.4.
FDG-PET analysis. To prospectively validate the significant findings from group 1 (1), metabolic activity
in each previously identified hypermetabolic region was measured for group 2 subjects (SLE-2 and HC-2)
using spherical (radius = 5 mm) volumes of interest (VOIs), centered at the peak voxel of each cluster and
normalized by dividing the global metabolic rate measured in each scan. To further assess abnormal regional metabolism in the SLE-2 subjects, a voxel-wise search of whole-brain volume using the SPM5 2-sample
t test option was performed to compare scans from the 20 SLE-2 subjects and the 25 HC-1/2. Moreover,
nearly identical subject selection protocols for SLE-1 and SLE-2 allowed us to combine the 37 SLE-1/2
scans and compare them with the 25 HC-1/2 scans in another voxel-wise search of whole-brain volume
using the SPM5 2-sample t test option. For significant regions identified in each SPM analysis, VOIs were
used to measure regional metabolism in each of the SLE-1/2 and HC-1/2 subjects. For both analyses, SPM
(T) maps were created and considered significant at the threshold of T ≥ 3.2, P < 0.001 (peak voxel, uncorrected). Regional metabolism was compared between the SLE-1/2 and HC-1/2 subjects or between the
SLE-1 and SLE-2 subjects using Student’s t tests in post hoc statistical analyses following the SPM imaging
analysis. Longitudinal changes in regional metabolism in the SLE-2 subjects were compared between baseline and follow-up (mean 14.9 months) using paired Student’s t tests.
DTI analyses — group differences. Voxel-wise searches for microstructural differences between SLE-2
and HC-3 groups at baseline were conducted using SPM8 software (http://www.fil.ion.ucl.ac.uk/spm/
software/spm8/). A WM mask in SPM template was applied in this analysis. The voxel-wise FA group
contrasts were considered significant at P = 0.001 at peak voxel, corrected for cluster extent at P < 0.05. We
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also reported regional differences at a hypothesis-testing threshold of P < 0.001 (voxel level uncorrected),
with a cluster cutoff of 100 voxels. Individual FA values from each significant cluster were computed for
each subject at the baseline and follow-up scans. The individual subject data were inspected for outliers and
overlapping values between the groups. Group differences were evaluated post hoc using Student’s t test.
Microstructural integrity changes over time were evaluated post hoc using paired Student’s t tests.
Tractography. Based on the assumption that the orientation of the longest axis (v1) of the diffusion tensor represents local fiber orientation (67), 3D streamlined information from the tensor field, called tractography, were reconstructed. This tractography method requires seeds from which streamlines are propagated
based on v1 orientations. The streamlines are terminated when they reach a low anisotropy region where
there is no coherent fiber organization. Voxel-based comparison of the FA maps for SLE-2 compared with
HC-3 subjects identified clusters with significantly reduced microstructural integrity that were used as seed
volumes for tractography. WM pathways passing through these clusters were reconstructed separately for
the two groups. The main purpose of showing these group fiber tracts was to visualize WM trajectories in
3 dimensions, particularly in relation to areas with abnormal microstructure (local FA) in the SLE brain.
This allowed us to identify the WM pathways associated with these abnormal clusters and to evaluate
potential disruption of anatomical connectivity in the SLE group occurring in the vicinity of these clusters.
Diffusion-weighted images from subjects in each group were registered to the template; the gradient vectors
were reoriented for tensor calculation (68, 69); and TrackVis (Massachusetts General Hospital; http://
www.trackvis.org/) was used to reconstruct and visualize the group tractography. The fiber-tracking program (Diffusion Toolkit) takes tensor files and generates whole-brain fiber tracks saved to a track data file.
The visualization program (TrackVis) utilizes the track data file to visualize the tracks. Tracking parameters
were identical for the two groups. The WM mask, the angle threshold of 35, and z-inversion were set up in
TrackVis. The reconstructed tracts were displayed for SLE-2 and HC-3.
Spatial memory test correlation. Voxel-wise correlations between FA maps and serum DNRAb titers in
SLE-2 subjects were assessed using regression analysis in SPM8 software. The voxel-wise contrasts were
considered significant at a hypothesis-testing threshold of P < 0.001 (voxel level uncorrected), with a cluster
cutoff of 100 voxels. Individual FA values from each significant cluster were computed for each subject.
Correlations between these FA values, serum DNRAb titers, and 2x2SMT scores were evaluated post hoc
using Pearson’s product-moment correlation coefficient.
All statistical tests in this study were considered significant at P < 0.05 and were 2 tailed.
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